Abrupt onset of Sweet syndrome, pityriasis rubra pilaris, pityriasis lichenoides et varioliformis acuta and erythema multiforme: unravelling a possible common trigger, the COVID-19 vaccine

doi: 10.1111/ced.14970

Dear Editor,

The development and manufacturing of effective vaccines against COVID-19 has been an epic achievement in record time, and we believe that the vaccine will help stop the pandemic. As with other medical interventions, vaccines may carry a small risk of adverse reactions (ARs), especially when used on large populations outside the highly controlled setting of Phase 3 clinical trials. We report five cases of different rare and severe cutaneous conditions arising in close connection with COVID-19 vaccination (Table 1).

By April 2021, about 15% of the 849 000 inhabitants of the province of Vicenza (in the Veneto region of northeast Italy) had been vaccinated, with a male:female ratio of 3:2. The priority was accorded to older people (> 80 years), healthcare workers and school staff. Overall, 187 adverse events were recorded. Besides the more common reactions reflecting aspecific activation of the immune system such as urticaria and cutaneous rash, we observed four rare acute conditions in five recently vaccinated patients [pityriasis rubra pilaris (PRP) in two patients, and Sweet syndrome (SS), pityriasis lichenoides et varioliformis acuta (PLEVA) and erythema multiforme (EM) in one patient each] (Fig. 1). All these conditions were confirmed histologically (Fig. 2) and appeared within the first 2 weeks following the first dose of the COVID-19 vaccine.

Table 1 Brief summary of the demographic and clinical features of the patients.

| Patient | Diagnosis | Sex | Age, years | Type of COVID-19 vaccine | Time lag, days | Comorbidities | Clinical course |
|---------|-----------|-----|------------|--------------------------|---------------|---------------|----------------|
| 1       | PRP       | F   | 62         | Moderna, first dose (second dose not administered) | 5             | Metabolic syndrome, T2DM, hypertensive heart disease, hypothyroidism, CKD | Progressive remission with systemic prednisone (1 mg/kg/day for 2 weeks, then tapered) and topical steroids at 1-month follow-up. Hospitalization for COVID-19 infection 4 months after PRP onset |
| 2       | PRP       | F   | 82         | Pfizer–BioNTech, first dose (second dose not administered) | 7             | Plaque and nail psoriasis, CLL, T2DM, hypertension, COPD | Clinical improvement achieved with subcutaneous MTX 15 mg/weekly. Residual PP hyperkeratosis and scaly plaques on head and neck at the 4-month follow-up |
| 3       | SS        | F   | 69         | Oxford–AstraZeneca, first dose (second dose not administered) | 12            | Overweight, hypertension, dyslipidaemia, iron-deficiency anaemia | Treated with steroid administration (prednisone 1 mg/kg/day for 4 weeks, then slow tapering). At 3-month follow-up, complete healing of the ulcerated plaques with residual hyperpigmentation |
| 4       | PLEVA     | M   | 70         | Pfizer–BioNTech, second dose | 5             | Acute lymphocytic leukaemia in complete remission | Treated with topical combination of fusidic acid 2% plus betamethasone cream 0.1%. Complete remission within 10 weeks |
| 5       | EM        | F   | 76         | Pfizer–BioNTech, first dose (second dose administered) | 4             | Lung adenocarcinoma (Stage IV), arterial hypertension, T2DM, COPD | Topical prescription of methylprednisolone 0.1% cream twice daily for 10 days. Complete clearance achieved in 10 days. No recurrence with the second vaccine dose |

CKD, chronic kidney disease; CLL, chronic lymphocytic leukaemia; COPD, chronic obstructive pulmonary disease; EM, erythema multiforme; PLEVA, pityriasis lichenoides et varioliformis acuta; PP, palmoplantar; PRP, pityriasis rubra pilaris; T2DM, Type 2 diabetes mellitus; MTX, methotrexate; SS, Sweet syndrome.
To better characterize the relationship between these possible ARs and vaccine administration, we used the Naranjo Adverse Drug Reaction Probability Scale, obtaining a score for each patient indicating a 'probable' causality link (Table 2). All patients had undergone a COVID-19 throat swab test 2 weeks prior to the vaccine, which was negative, and none of them had been infected since the pandemic started. None of the patients had any medical history of previous ARs to drugs or vaccines, or of any dermatological disorders.

A number of cutaneous conditions following COVID-19 immunization have been reported, most of which were mild and self-limiting such as local injection-site reactions, and urticarial and morbilliform eruptions. In addition, some rare reactions have been observed including chilblains, cosmetic filler reactions, flares of herpes zoster or simplex, pityriasis rosea-like reactions, EM and SS. Our observations confirm the possible association of COVID-19 vaccination with both EM and SS. In addition, this case series expands on the spectrum of possible vaccine ARs to include PRP and PLEVA.

There is a debate about the capacity of COVID-19 vaccines to trigger immune-mediated conditions, either with exacerbation of pre-existing or new onset of immune-mediated disorders. These events may result from upregulated inflammatory immunological pathways or crossreactivity between viral or adjuvant molecules and self-antigens. Other vaccines have been associated with immune-mediated cutaneous ARs, including EM, cutaneous lupus, Gianotti–Crosti syndrome, lichenoid eruption and granuloma annulare, and also a few cases of SS, PRP and PLEVA.
The causal relationship between mRNA vaccines and cutaneous immunological reactions is still under debate, and we cannot exclude that the events we have reported were purely coincidental. Systemic surveillance and accurate reporting are essential to estimate associations and better qualify the potentially at-risk population, defining effective management strategies.

A. Sechi,1,2 E. Pierobon,3 E. Pezzolo,1 L. Germi,1 G. Trevisan,1 D. Zardo,4 G. Riva,4 S. Mondino5 and L. Naldi1
1Dermatology Unit, Ospedale San Bortolo, Vicenza, Italy; 2IRCCS University Hospital of Bologna S Orsola-Malpighi Polyclinic Dermatology Division, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Alma Mater Studiorum University of Bologna, Bologna, Italy; 3Section of Dermatology, Department of Medicine and Surgery, University of Parma, Parma, Italy; 4Pathology Unit and 5Health and Risk Management, Ospedale San Bortolo, Vicenza, Italy
E-mail: andrea.sechi@hotmail.com
Conflict of interest: the authors declare that they have no conflicts of interest.
AS and EP contributed equally to this work and should be considered joint first authors.
Accepted for publication 7 August 2021

References
1 Naranjo CA, Busto U, Sellers EM et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239–45.
2 McMahon DE, Amerson E, Rosenbach M et al. Cutaneous reactions reported after Moderna and Pfizer COVID-19
Validation of the RECap of AtoPic eczema measure of eczema control for use in dermatology clinics

do: 10.1111/ced.14934

Dear Editor,

The Harmonising Outcome Measures for Eczema (HOME) initiative seeks to standardize outcome measures in trials of eczema treatments.1 The RECap for AtoPic eczema (RECAP) questionnaire is a seven-item HOME-recommended patient-reported outcome measure of eczema control.2 The total score of RECAP is from 0 to 28, with higher scores indicating poorer eczema control. In an online survey of 382 participants, RECAP was found to have good validity and reliability.3 However, the validity and reliability of questionnaires can vary by both population and setting. We investigated the acceptability and validity of RECAP in a clinic setting in Bristol, England.

The study was approved by Yorkshire and The Humber – South Yorkshire research ethic committee (reference no. 25901) and sponsored by the University of Bristol.

Adults with eczema and parents of children with eczema attending hospital dermatology outpatient clinics and a nurse-led community dermatology clinic were invited to complete a paper-based questionnaire. The questionnaire included RECAP together with Patient-reported Eczema Severity (POEM) and the Patient-reported Outcomes Measurement Information System (PROMIS) quality of life (QoL) tools, both of which have been shown to have good validity.4,5

To evaluate the construct validity of RECAP, the following hypotheses were prespecified: (i) eczema control worsens with increasing disease severity; (ii) poorer eczema control is associated with worse QoL; and (iii) eczema control worsens with disease ‘bother’ (How much bother has your eczema been over the past week?: 0, none, 10, maximum). A self-reported improvement/worsening in eczema would equate to a decrease/increase in RECAP score.

Our target sample size was 98, but participant recruitment had to be stopped early because of the COVID-19